PetDx Announces Publication of Landmark Clinical Validation Study for OncoK9, Its Pioneering Multi-Cancer Early Detection Test for Dogs Using Next-Generation Sequencing
Published in PLOS ONE, the CANcer Detection in Dogs (CANDiD) study–the largest clinical validation study in veterinary cancer diagnostics–sets a new benchmark for veterinary medicine
Veterinarians Using OncoK9 Liquid Biopsy Test in Complex Clinical Cases Can Consult with Specialists Through the Fidu Telemedicine Platform
Access to Internal Medicine and Oncology Consultations Will Support Veterinarians Prescribing First-in-Class Multi-Cancer Early Detection (MCED) Test from PetDx®
The collaborative effort makes OncoK9 available immediately to veterinary customers served by IDEXX Reference Laboratories
PetDx Raises $62 Million in Series B Financing to Scale Adoption of its Canine Multi-Cancer Early Detection Blood Test, OncoK9
OncoK9® is a first-in-class multi-cancer early detection (MCED) test that employs next-generation sequencing (NGS) to detect many types of cancer in dogs with a simple blood draw.
OncoK9 Initially Available at Select Petco Full-Service Veterinary Hospitals Beginning in May